HIV Infections Clinical Trial
Official title:
Psychosocial Correlates and Coping Strategies Associated With Long-Term Survival of HIV-Infected Children
Children and adolescents with HIV/AIDS are living well beyond life expectancy that was projected for them in the recent past. Little is known about the psychosocial variables that coincide with long-term survival of HIV/AIDS. This longitudinal study examines the psychosocial factors and adaptive coping strategies associated with long-term survival of HIV/AIDS in children and how these factors change over a period of two years. In addition, data is being collected from the primary caretakers on their own psychological well-being as will as their perceptions of their child's adjustment and coping. Participants include children who have been infected (either perinatally or through transfusion) for at least eight years and who were aware of their diagnosis.
Children and adolescents with HIV/AIDS are living well beyond the life expectancy that was
projected for them in the recent past. Little is known about the psychosocial variables that
coincide with long-term survival of HIV/AIDS. This longitudinal study will examine the
psychosocial factors and adaptive coping strategies associated with long-term survival of
HIV/AIDS and how these factors change over a period of three years. In addition, data will
be collected from the primary caretakers on both their own and their perceptions of their
child's adjustment and coping. Subjects will include children who have been infected (either
perinatally or through transfusion) for at least eight years and who are aware of their
diagnosis.
Studies of children with chronic illnesses report that adaptive coping strategies such as
maintaining a hopeful attitude, social support and information seeking may affect
psychological adjustment and help to buffer the negative psychological effects that a
chronic illness may have. HIV-infected children not only have the added stress of living
with debilitating and progressive symptoms in a disease that threatens their life spans, but
their disease often stigmatizes them and causes them to be ostracized. The largest
proportion of children with HIV disease acquired it perinatally, and therefore the mother is
also infected. Thus it is expected that these families have at least two infected natural
family members, causing multigenerational effect in terms of epidemiology, multiple
separations and the death of close family members. As a result, children need to develop
coping strategies in order to deal effectively with this disease.
Preliminary results from a longitudinal study assessing psychiatric disturbances in
HIV-infected, school-aged children indicate that these children exhibit elevated levels of
separation anxiety, depression and overanxious disorder. Whether similar results will be
found in older HIV-infected children is not yet known. Research that can identify the coping
resources, such as social support, family communication styles, hopefulness and quality of
life, that 1) buffer the negative effects of stress on the mental health of HIV-infected
children and 2) identify areas of vulnerability, would be important in our attempts to
design early mental health interventions.
The HIV-infected child's perceived social support, self-esteem, psychological adjustment,
and adaptive coping will be based on self-reports from the child. The caretakers will also
give ratings of the child's adjustment in addition to providing information on how they feel
their child has changed in the past year. Caretakers will complete measures regarding family
environment, their own adjustment, and demographic variables. The child's health care
provider will complete a questionnaire assessing his/her current health status. The effects
of age and disease progression in both the child and parent will be taken into account for
the final analysis of this study.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |